192 related articles for article (PubMed ID: 22671925)
1. Molecular targets for the treatment of multiple myeloma.
Rossi M; Di Martino MT; Morelli E; Leotta M; Rizzo A; Grimaldi A; Misso G; Tassone P; Caraglia M
Curr Cancer Drug Targets; 2012 Sep; 12(7):757-67. PubMed ID: 22671925
[TBL] [Abstract][Full Text] [Related]
2. Novel targets and derived small molecule inhibitors in multiple myeloma.
Podar K
Curr Cancer Drug Targets; 2012 Sep; 12(7):797-813. PubMed ID: 22671928
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
Palumbo A; Sonneveld P
Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: Implementing signaling pathways and molecular biology in clinical trials.
Bazzi M; Badros A
Cancer Biol Ther; 2010 Nov; 10(9):830-8. PubMed ID: 21045554
[TBL] [Abstract][Full Text] [Related]
5. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
6. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma.
Harvey RD; Lonial S
Future Oncol; 2007 Dec; 3(6):639-47. PubMed ID: 18041916
[TBL] [Abstract][Full Text] [Related]
7. Targeting Bcl-2 for the treatment of multiple myeloma.
Touzeau C; Maciag P; Amiot M; Moreau P
Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
[TBL] [Abstract][Full Text] [Related]
8. AKT as a therapeutic target in multiple myeloma.
Keane NA; Glavey SV; Krawczyk J; O'Dwyer M
Expert Opin Ther Targets; 2014 Aug; 18(8):897-915. PubMed ID: 24905897
[TBL] [Abstract][Full Text] [Related]
9. Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
Magarotto V; Salvini M; Bonello F; Bringhen S; Palumbo A
Leuk Lymphoma; 2016; 57(3):537-56. PubMed ID: 26445358
[TBL] [Abstract][Full Text] [Related]
10. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
Wong SW; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
[TBL] [Abstract][Full Text] [Related]
11. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.
Lonial S
Cancer J; 2016; 22(1):3-6. PubMed ID: 26841009
[TBL] [Abstract][Full Text] [Related]
13. Impact of bortezomib on bone health in myeloma: a review of current evidence.
Zangari M; Terpos E; Zhan F; Tricot G
Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
15. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
Jelinek T; Paiva B; Hajek R
Front Immunol; 2018; 9():2431. PubMed ID: 30505301
[TBL] [Abstract][Full Text] [Related]
16. Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.
Anwer F; Gee KM; Iftikhar A; Baig M; Russ AD; Saeed S; Zar MA; Razzaq F; Carew J; Nawrocki S; Al-Kateb H; Cavalcante Parr NN; McBride A; Valent J; Samaras C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):397-405. PubMed ID: 31036508
[TBL] [Abstract][Full Text] [Related]
17. Management of myeloma: an Italian perspective.
Bruno B; Gay F; Boccadoro M; Palumbo A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
[TBL] [Abstract][Full Text] [Related]
18. Targeting signaling pathways in multiple myeloma: Pathogenesis and implication for treatments.
Hu J; Hu WX
Cancer Lett; 2018 Feb; 414():214-221. PubMed ID: 29174802
[TBL] [Abstract][Full Text] [Related]
19. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
Bieghs L; Johnsen HE; Maes K; Menu E; Van Valckenborgh E; Overgaard MT; Nyegaard M; Conover CA; Vanderkerken K; De Bruyne E
Oncotarget; 2016 Jul; 7(30):48732-48752. PubMed ID: 27129151
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs in multiple myeloma.
Ghobrial IM; Leleu X; Hatjiharissi E; Hideshima T; Mitsiades C; Schlossman R; Anderson KC; Richardson P
Expert Opin Emerg Drugs; 2007 Mar; 12(1):155-63. PubMed ID: 17355220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]